Capricor Called HOPE-3 a Success, FDA Says Deramiocel Evidence Falls Short

Capricor Therapeutics shares plunged about 65% on Monday after FDA reviewers questioned whether deramiocel benefits patients with Duchenne muscular dystrophy. The agency released its assessment before a July 29 advisory committee meeting. Although Capricor calls HOPE-3 Phase 3 study positive,